Topas Therapeutics raises EUR 22 Million in Series B Financing and appoints new CEO

Topas Therapeutics announced today the appointment of Klaus Martin, Ph.D., as Chief Executive Officer and the successful closing of a €22 million (~$26 million) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas’ existing investors.